NIH reports promising data on remdesivir for aiding COVID-19 recovery
A trial sponsored by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases provided preliminary indications that hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received a placebo.
Remdesivir is an investigational, broad-spectrum antiviral treatment administered via daily infusion for 10 days.
The randomized, controlled trial, which involved more than 1,000 patients from multiple sites around the world, found that patients who received remdesivir had a 31% faster recovery time, compare with those who received a placebo — 11 days for patients treated with remdesivir, compared with 15 days for those in the control group.
Related News Articles
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…